Background: Diabetes Mellitus (DM) may occur in IBD and influence the disease progression. Aim: To compare disease course and treatment outcomes in IBD patients with and without DM. Methods: This is a systematic review with meta-analysis comparing patients with IBD plus DM with patients with IBD only. Primary endpoints: need for surgery, IBD-related complications, hospitalizations, sepsis, mortality. Quality of life and costs were assessed. Results: Five studies with 71,216 patients (49.1% with DM) were included. Risk for IBD-related complica- tions (OR = 1.12, I 2 98% p = 0.77), mortality (OR = 1.52, I 2 98% p = 0.37) and IBD-related surgery (OR = 1.20, I 2 81% p = 0.26) did not differ. Risk of IBD-related hospitalizations (OR = 2.52, I 2 0% p < 0.0 0 0 01) and sep- sis (OR = 1.56, I 2 88% p = 0.0 0 03) was higher in the IBD + DM group. Risk of pneumonia and urinary tract infections was higher in the IBD + DM group (OR = 1.72 and OR = 1.93), while risk of C. Difficile infection did not differ (OR = 1.22 I 2 88% p = 0.37). Mean Short Inflammatory Bowel Disease Questionnaire score was lower in the IBD + DM group (38.9 vs. 47, p = 0.03). Mean health care costs per year were $10,598.2 vs $3747.3 ( p < 0.001). Conclusion: DM might negatively affect the course of IBD by increasing the risk of hospitalization and infections, but not IBD-related complications and mortality.
Fuschillo, G., Celentano, V., Rottoli, M., Sciaudone, G., Gravina, A.G., Pellegrino, R., et al. (2022). Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis. DIGESTIVE AND LIVER DISEASE, epub ahed of print, 1-7 [10.1016/j.dld.2022.08.017].
Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis
Rottoli, Matteo;
2022
Abstract
Background: Diabetes Mellitus (DM) may occur in IBD and influence the disease progression. Aim: To compare disease course and treatment outcomes in IBD patients with and without DM. Methods: This is a systematic review with meta-analysis comparing patients with IBD plus DM with patients with IBD only. Primary endpoints: need for surgery, IBD-related complications, hospitalizations, sepsis, mortality. Quality of life and costs were assessed. Results: Five studies with 71,216 patients (49.1% with DM) were included. Risk for IBD-related complica- tions (OR = 1.12, I 2 98% p = 0.77), mortality (OR = 1.52, I 2 98% p = 0.37) and IBD-related surgery (OR = 1.20, I 2 81% p = 0.26) did not differ. Risk of IBD-related hospitalizations (OR = 2.52, I 2 0% p < 0.0 0 0 01) and sep- sis (OR = 1.56, I 2 88% p = 0.0 0 03) was higher in the IBD + DM group. Risk of pneumonia and urinary tract infections was higher in the IBD + DM group (OR = 1.72 and OR = 1.93), while risk of C. Difficile infection did not differ (OR = 1.22 I 2 88% p = 0.37). Mean Short Inflammatory Bowel Disease Questionnaire score was lower in the IBD + DM group (38.9 vs. 47, p = 0.03). Mean health care costs per year were $10,598.2 vs $3747.3 ( p < 0.001). Conclusion: DM might negatively affect the course of IBD by increasing the risk of hospitalization and infections, but not IBD-related complications and mortality.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
